Successfully introducing new drugs and therapies in a quicker and more cost-effective manner starts in the most complex phase on of drug development; the clinical phase. The implementation of risk-based monitoring increases the overall quality of data while providing better oversight of patient safety. With the introduction of centralized monitoring in a risk-based monitoring approach, pharmaceutical companies are able to embrace a real-time overview of data and risk detection. The Central Monitoring Summit will arm delegates with the tools they need to optimize existing clinical operation platforms and build quality into the design for a sound central monitoring foundation. Join your colleagues and our expert speaking staff as they provide in-depth insights into shifting your monitoring processes from an excessive concentration of data to risk-driven monitoring that uses central monitoring and technology enablement.